Investor Center Home

Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Change Stock is Down 0.39
(%)Volume (2.21%)186,711
Data as of 08/31/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
08/08/16Bellicum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/04/16Bellicum Announces BPX-501 European Regulatory UpdatesPrinter Friendly Version
08/01/16Bellicum to Report Second Quarter 2016 Financial Results and Host Conference Call and Webcast on August 8, 2016Printer Friendly Version
07/20/16Bellicum Pharmaceuticals Announces Patent on CaspaCIDe Method for Selectively Eliminating Therapeutic CellsPrinter Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Past Events
08/08/16 5:00 p.m. ET
Q2 2016 Bellicum Pharmaceuticals Inc Earnings Conference Call
Click here for webcast
06/15/16 10:00 a.m. CT
Bellicum Pharmaceuticals, Inc. Annual Shareholder Meeting
Location: Meeting Room, 8th Floor
Bellicum Pharmaceuticals, Inc.
2130 West Holcombe Blvd.
Houston, TX 77030
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources